- Conditions
- Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
- Interventions
- BBP-418 (ribitol), Placebo
- Drug · Other
- Lead sponsor
- ML Bio Solutions, Inc.
- Industry
- Eligibility
- 12 Years to 60 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 13
- States / cities
- Little Rock, Arkansas • Irvine, California • Aurora, Colorado + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2161–2184
of 7,462
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV-1-infection, Human Immunodeficiency Virus, HIV/AIDS, HIV Infections
- Interventions
- Prevnar-13
- Biological
- Lead sponsor
- VA Eastern Colorado Health Care System
- Federal
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2028
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Tolebrutinib, Teriflunomide, Placebo to match Tolebrutinib, Placebo to match Teriflunomide
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 974 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 18 more
- Conditions
- Benign Prostatic Hypertrophy
- Interventions
- Cetrorelix 78 mg + 78 mg, Cetrorelix 78 mg + 52 mg, Placebo
- Drug
- Lead sponsor
- AEterna Zentaris
- Industry
- Eligibility
- 50 Years and older · Male only
- Enrollment
- 667 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 46
- States / cities
- Huntsville, Alabama • Fort Smith, Arkansas • Laguna Hills, California + 39 more
- Conditions
- Obesity
- Interventions
- NNC0519-0130, Placebo, Tirzepatide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 354 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 49
- States / cities
- Mesa, Arizona • Little Rock, Arkansas • Searcy, Arkansas + 40 more
- Conditions
- HIV Infections
- Interventions
- Abacavir sulfate, Lamivudine and Zidovudine, Atazanavir, Lamivudine/Zidovudine, Abacavir sulfate, Efavirenz, Nevirapine, Lamivudine, Stavudine, Zidovudine, Didanosine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 16 Years and older
- Enrollment
- 1,125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2005
- U.S. locations
- 59
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 34 more
- Conditions
- Migraine
- Interventions
- Migraine Prophylactic Therapy Only, Discontinuation of Overused Medication
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 720 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 29
- States / cities
- Flagstaff, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 21 more
- Conditions
- Gastrointestinal Neoplasms
- Interventions
- IDRX-42, Sunitinib
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Duarte, California • La Jolla, California + 42 more
- Conditions
- Phenylketonuria
- Interventions
- PTC923, Placebo
- Drug
- Lead sponsor
- PTC Therapeutics
- Industry
- Eligibility
- Not listed
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 12
- States / cities
- Stanford, California • Aurora, Colorado • Gainesville, Florida + 9 more
- Conditions
- Brain Edema, Brain Tumor
- Interventions
- hCRF, placebo hCRF
- Drug
- Lead sponsor
- Celtic Pharma Development Services
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • La Jolla, California • Newport Beach, California + 20 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- PLN-74809, Placebo
- Drug
- Lead sponsor
- Pliant Therapeutics, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 79
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 69 more
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer, Solid Cancers
- Interventions
- GDC-0941, erlotinib HCl
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • New Brunswick, New Jersey
- Conditions
- Chronic Hepatitis B
- Interventions
- TAF, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2029
- U.S. locations
- 15
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 12 more
- Conditions
- Nasal Polyps
- Interventions
- Depemokimab (GSK3511294), Placebo
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 276 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 26
- States / cities
- Tucson, Arizona • Buena Park, California • Los Angeles, California + 22 more
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody, Nab-Paclitaxel, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 902 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Springdale, Arkansas • Oakland, California + 42 more
- Conditions
- Respiratory Syncytial Viruses, Respiratory Syncytial Virus Infections
- Interventions
- RSVPreF3 OA investigational vaccine, HZ/su vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 530 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 11
- States / cities
- Daphne, Alabama • Tempe, Arizona • Corte Madera, California + 8 more
- Conditions
- Multiple Sclerosis
- Interventions
- Diroximel Fumarate, Avonex, Tysabri, Dimethyl Fumarate
- Drug · Biological
- Lead sponsor
- Biogen
- Industry
- Eligibility
- Female only
- Enrollment
- 908 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Durham, North Carolina
- Conditions
- AML, MDS
- Interventions
- NKR-2
- Biological
- Lead sponsor
- Celyad Oncology SA
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Tampa, Florida • Atlanta, Georgia + 1 more
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- Amivantamab, Pembrolizumab, Paclitaxel, Carboplatin
- Biological · Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 287 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2033
- U.S. locations
- 15
- States / cities
- La Jolla, California • Aurora, Colorado • New Haven, Connecticut + 12 more
- Conditions
- Ovarian Cancer
- Interventions
- Cryopreservation of gonadal tissue
- Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Leukemia
- Interventions
- BioIntelliSense BioButton Rechargable, Memora Health two-way patient engagement platform provided by RC
- Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Neurocognitive Dysfunction
- Interventions
- Transseptal Aortic Approach Catheter Ablation Procedure, Retrograde Aortic Approach Catheter Ablation Procedure
- Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 14 more
- Conditions
- Advanced/Metastatic Solid Tumors or Lymphomas
- Interventions
- ADU-S100, ipilimumab
- Drug · Biological
- Lead sponsor
- Chinook Therapeutics, Inc. (formerly Aduro)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 7
- States / cities
- Aurora, Colorado • Chicago, Illinois • Baltimore, Maryland + 4 more
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Diffuse Intrinsic Pontine Glioma, Gliosarcoma
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Vorinostat
- Radiation · Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 37 Months to 21 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2021
- U.S. locations
- 174
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 129 more